Geron GERN Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Arcus BiosciencesRCUS

——

Tango TherapeuticsTNGX

——

ExelixisEXEL

——

Jazz PharmaceuticalsJAZZ

——

Gilead SciencesGILD

——

BiogenBIIB

——

Other financials

Income statement

See full

Revenue$51.8M+30.9%

Operating income$158.0K+101%

Net income-$3.6M+81.6%

EPS (diluted)-$0.01+66.7%

Balance sheet

See full

Cash & equivalents$48.7M-12.2%

Total debt$134.0M+10.0%

Total equity$229.1M-14.6%

Total assets$534.1M-5.0%

Cash flow

See full

Operating cash flow-$62.9M-31.1%

CapEx$206.0K+2.0%

Free cash flow-$43.8M-6.8%

Valuation

See full

Market cap$878.88M-8.6%

Enterprise value$964.15M-6.2%

P/S4.7×-172×

Profitability

See full

Operating margin-705.5%-351pp

Net margin-682.5%-339pp

FCF margin-734.4%-365pp

Returns & leverage

See full

Return on equity-27.1%-7.8pp

Debt / equity0.6×+0.1×

Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Geron's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?: Geron (GERN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $215K in Q1 2026.
How has Geron's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?: Geron's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 424.4% year-over-year, from $41K to $215K.